These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 35588144)

  • 1. Synergy of a STING agonist and an IL-2 superkine in cancer immunotherapy against MHC I-deficient and MHC I
    Wolf NK; Blaj C; Picton LK; Snyder G; Zhang L; Nicolai CJ; Ndubaku CO; McWhirter SM; Garcia KC; Raulet DH
    Proc Natl Acad Sci U S A; 2022 May; 119(22):e2200568119. PubMed ID: 35588144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NK cells mediate clearance of CD8
    Nicolai CJ; Wolf N; Chang IC; Kirn G; Marcus A; Ndubaku CO; McWhirter SM; Raulet DH
    Sci Immunol; 2020 Mar; 5(45):. PubMed ID: 32198222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine therapy reverses NK cell anergy in MHC-deficient tumors.
    Ardolino M; Azimi CS; Iannello A; Trevino TN; Horan L; Zhang L; Deng W; Ring AM; Fischer S; Garcia KC; Raulet DH
    J Clin Invest; 2014 Nov; 124(11):4781-94. PubMed ID: 25329698
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD4
    Doorduijn EM; Sluijter M; Salvatori DC; Silvestri S; Maas S; Arens R; Ossendorp F; van der Burg SH; van Hall T
    Cancer Immunol Res; 2017 Aug; 5(8):642-653. PubMed ID: 28637878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy.
    Lv M; Chen M; Zhang R; Zhang W; Wang C; Zhang Y; Wei X; Guan Y; Liu J; Feng K; Jing M; Wang X; Liu YC; Mei Q; Han W; Jiang Z
    Cell Res; 2020 Nov; 30(11):966-979. PubMed ID: 32839553
    [TBL] [Abstract][Full Text] [Related]  

  • 6. STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation.
    Nakamura T; Sato T; Endo R; Sasaki S; Takahashi N; Sato Y; Hyodo M; Hayakawa Y; Harashima H
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34215690
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Combination doxorubicin and interferon-α therapy stimulates immunogenicity of murine pancreatic cancer Panc02 cells via up-regulation of NKG2D ligands and MHC class I.
    Wang WJ; Qin SH; Zhang JW; Jiang YY; Zhang JN; Zhao L
    Asian Pac J Cancer Prev; 2014; 15(22):9667-72. PubMed ID: 25520086
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy.
    Murer P; Brannetti B; Rondeau JM; Petersen L; Egli N; Popp S; Regnier C; Richter K; Katopodis A; Huber C
    MAbs; 2024; 16(1):2381891. PubMed ID: 39041287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
    Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
    J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neoadjuvant STING Activation, Extended Half-life IL2, and Checkpoint Blockade Promote Metastasis Clearance via Sustained NK-cell Activation.
    Milling LE; Garafola D; Agarwal Y; Wu S; Thomas A; Donahue N; Adams J; Thai N; Suh H; Irvine DJ
    Cancer Immunol Res; 2022 Jan; 10(1):26-39. PubMed ID: 34686488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cooperative therapeutic anti-tumor effect of IL-15 agonist ALT-803 and co-targeting soluble NKG2D ligand sMIC.
    Basher F; Jeng EK; Wong H; Wu J
    Oncotarget; 2016 Jan; 7(1):814-30. PubMed ID: 26625316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting interferon signaling and CTLA-4 enhance the therapeutic efficacy of anti-PD-1 immunotherapy in preclinical model of HPV
    Dorta-Estremera S; Hegde VL; Slay RB; Sun R; Yanamandra AV; Nicholas C; Nookala S; Sierra G; Curran MA; Sastry KJ
    J Immunother Cancer; 2019 Sep; 7(1):252. PubMed ID: 31533840
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indirect Impact of PD-1/PD-L1 Blockade on a Murine Model of NK Cell Exhaustion.
    Alvarez M; Simonetta F; Baker J; Morrison AR; Wenokur AS; Pierini A; Berraondo P; Negrin RS
    Front Immunol; 2020; 11():7. PubMed ID: 32117218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.
    Neal ZC; Imboden M; Rakhmilevich AL; Kim KM; Hank JA; Surfus J; Dixon JR; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2004 Jan; 53(1):41-52. PubMed ID: 14504825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The level of MHC class I expression on murine adenocarcinoma can change the antitumor effector mechanism of immunocytokine therapy.
    Imboden M; Murphy KR; Rakhmilevich AL; Neal ZC; Xiang R; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Res; 2001 Feb; 61(4):1500-7. PubMed ID: 11245457
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of the phenotype and function of CD8(+), alpha / beta(+) NKT cells from tumor-bearing mice that show a natural killer cell activity and lyse multiple tumor targets.
    Stremmel C; Exley M; Balk S; Hohenberger W; Kuchroo VK
    Eur J Immunol; 2001 Sep; 31(9):2818-28. PubMed ID: 11536181
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing Natural Killer and CD8
    Ravindranath MH; Filippone EJ; Devarajan A; Asgharzadeh S
    Monoclon Antib Immunodiagn Immunother; 2019 Apr; 38(2):38-59. PubMed ID: 31009335
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It.
    Shklovskaya E; Rizos H
    Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201655
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.